Dr. Ruben Mesa on the SURPASS-ET Trial and Unmet Needs in Essential Thrombocythemia

3 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Ruben Mesa, MD, of the Atrium Health Wake Forest Baptist Comprehensive Cancer Center, discussed the phase 3 SURPASS-ET trial of ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia (ET) presented at the 2025 American Society of Clinical Oncology Annual Meeting.

Dr. Mesa outlined key efficacy and safety data for this patient population, as well as unmet needs in clinical trials for patients with ET.

“What we observed was superiority of ropeginterferon at both 9 and 12 months with a primary endpoint, Modified European LeukemiaNet response, which is a composite between control of blood counts, absence of vascular events, and improvement or no progression in both spleen and symptoms,” Dr. Mesa explained. “There were clear differences in terms of improvement in the JAK2V617F allele burden, which makes us hopeful that this will have a significant impact on decreasing the long-term progression of the disease as we follow these patients over time.”
Category
Oncology
Be the first to comment

Up Next